Genmab — November 2017
-
The four STOMP presentations will include updated data from the arms evaluating selinexor in combination with Velcade
(bortezomib) and low-dose dexamethasone (SVd), selinexor in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (SPd), and selinexor in combination with Revlimid (lenalidomide) and low-dose dexamethasone (SRd), and preliminary data from the arm evaluating selinexor in combination with Darzalex (daratumumab) and low-dose dexamethasone (SDd). -
-
Conclusions – Selinexor 100 mg QW, can be combined safely with daratumumab and dex. The activity observed in the first 3 pts is promising with all 3 pts responding to therapy. Enrollment is ongoing and updated data from 100 mg QW cohort, 100 mg QW expansion, and full phase 1 will be updated and presented.
-
Poseida Therapuetics paper on CAR-T; apparantly they are collaborating with J&J’s Janss
en to develop this... didn't know that... https://ash.confex.com/ash/2017/webprogram/Paper108439.html -
After 3 years of median follow-up, single-agent DARA continues to demonstrate a favorable safety profile with no new safety signals. Deep and durable responses continue to be maintained in a subset of these heavily pretreated patients. With over one-third of patients remaining alive after 3 years of study entry, these findings highlight the activity of single-agent DARA
-
-
An accelerated infusion rate of daratumumab delivering 20% of the dose over 30 minutes and 80% over 60 minutes is feasible and well-tolerated in patients who have received 2 prior doses of daratumumab at standard infusion rates. Starting with the third dose of daratumumab therapy, the 90-minute infusion is now standard practice at our institution. https://ash.confex.com/ash/2017/webprogram/Paper102870.html
-
-
Mens vi venter på Alcyone skal vi ikke glemme, at der faktisk er andre frontline-data på ASH. 2 abstracts om dara-CyBorD, hvoraf det ene (det lille rent irske) melder om lovende effektivitets-data. Mig bekendt de første effektivitets-data vi hører om fra frontline. https://ash.confex.com/ash/2017/webprogram/Paper101050.html
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind